medigraphic.com
Órgano de Difusión de la Asociación Académica Panamericana de Medicina Familiar A.C.

2023, Number 2

<< Back

Arch Med Fam 2023; 25 (2)

Dilated Cardiomyopathy: Presentation of a Clinical Case

Boned BP, Marco LC, Callejas GI

Language: Spanish
References: 9
Page: 103-106
PDF size: 404.20 Kb.


ABSTRACT

Dilated cardiomyopathy is a primary myocardial disease that in most cases has an idiopathic cause and it is defined by the presence of dilation and systolic dysfunction affecting the left ventricle or both ventricles. The clinical spectrum varies from asymptomatic patients to patients in cardiogenic shock. We present the clinical case of a 41-year-old man who presented clinical symptoms of heart failure.


REFERENCES

  1. Juan Pablo Costabel, Florencia Mandó, Gustavo Avegliano. Miocardiopatíadilatada: ¿cuándo y cómo proceder a la investigaciónetiológica? Rev Urug Cardiol 2018; 33: 343-349

  2. P.Elliott, B.Andersson, E.Arbustini. Classification of the cardiomyopathies:a position statement from the European Society of CardiologyWorking Group on Myocardial and Pericardial Diseases. Eur Heart J.,29 (2008), pp 270-276

  3. P.Elliott, A.Anastasakis, M.A. Borger et al. 2014 ESC Guidelines ondiagnosis and management of hypertrophic cardiomyopathy: TheTask Force for the diagnosis and management of Hypertrophiccardiomyopathy of the European Society of Cardiology (ESC). EurHeart J, 35 (2014), pp 2733-2779

  4. Pinto YM, Elliott PM, Arbustini E, Adler Y, Anastasakis A, Böhm M,et al. Proposal for a revised definition of dilated cardiomyopathy,hypokinetic non-dilated cardiomyopathy, and its implications forclinical practice: a position statement of the ESC working group onmyocardial and pericardial diseases. Eur Heart J. 2016;37(23):1850-8.

  5. Escobar-Lopez L, Ochoa JP, Mirelis JG et al. Association of geneticvariants with outcomes in patients with nonischemic dilated cardiomyopathy.J Am Coll Cardiol. 2021 Oct, 78 (17) 1682-1699.

  6. Spoladore, M.S. Maron, R. D’Amato, et al. Pharmacologicaltreatment options for hypertrophic cardiomyopathy: high time forevidence. European Heart Journal, 33 (2012), pp. 1724-1733

  7. Sherrid MV, A. Shetty, G. Winson, et al. Treamentment of obstructivehypertrophic cardiomyopathy symptoms and gradient resistant tofirst-line therapy with beta-blockade or verapamil. Circulation: HeartFailure, 6 (2013), pp. 694-702

  8. Hamada M, S. Ikeda, Y. Shigematsu. Advances in medical treatmentoh hypertrophic cardiomyopathy. Journal of Cardiology, 64 (2014),pp. 1-10

  9. Amor-Salamanca A, Guzzo-Merello G, González-López E et al.Impacto pronóstico y factores predictores de la recuperación dela fracción de eyección en pacientes con miocardiopatía dilatadaalcohólica. Rev Esp Cardiol. 2018;71:612-9.




2020     |     www.medigraphic.com